Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders
NCT06872333Phase 2Recruiting
- Sponsor
- Masonic Cancer Center
- Start
- Nov 2024
- Primary completion
- Jun 2030
- Countries
- 1
01
Overview
Phase 2, open-label trial of allogeneic hematopoietic stem cells in sickle cell disease (SCD), alpha thalassemia, beta thalassemia and 1 more (5 arms), sponsored by Masonic Cancer Center. Primary endpoint: Incidence of Graft versus Host Disease at 1 year. Started Nov 2024; status: recruiting.
02
Drugs
allogeneic hematopoietic stem cells
03
Conditions
sickle cell disease (SCD)alpha thalassemiabeta thalassemiaDiamond-Blackfan anemia (DBA)
Beyond the preview
Go deeper on NCT06872333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06872333.